MicroRNAs may be key to HIV's ability to hide, evade drugs, Jefferson scientists findOctober 01, 2007(PHILADELPHIA) Tiny pieces of genetic material called microRNA (miRNA), better known for its roles in cancer, could be a key to unlocking the secrets of how HIV, the AIDS virus, evades detection, hiding in the immune system. Researchers at Jefferson Medical College in Philadelphia have shown that when an individual infected with HIV receives a powerful cocktail of antiviral agents called HAART (highly active antiretroviral therapy), the virus calls on miRNAs to help it remain quiet and practically undetectable, temporarily shutting down its ability to replicate and infect. The work, which appears September 30, 2007 in an early online edition of the journal Nature Medicine, may also have implications for new treatment strategies against the virus. According to Hui Zhang, M.D., Ph.D., associate professor of Medicine in the Division of Infectious Diseases at Jefferson Medical College of Thomas Jefferson University, who led the work, if researchers can learn to manipulate miRNA's inhibitory effect on HIV, they might be able to devise strategies to bring the virus out of hiding, or "latency," making it vulnerable to drugs and the body's immune system. While HAART can drive the number of HIV particles in the blood to practically undetectable levels, the virus is not eliminated. It hides in "resting" immune system CD4 T cells in the body, including the testis, brain, and other places. The drug combination has to be taken the rest of the patient's life; if halted, the virus becomes active again.
"HIV latency and how to eliminate the replication-competent - and hidden - virus are big problems," Dr. Zhang explains, noting that the molecular mechanisms that are responsible for latency are unclear. Dr. Zhang, post-doctoral fellow Jialing Huang, Ph.D., and their colleagues may have come across one possible explanation. HIV, they have found, recruits cellular miRNA - noncoding genetic material that has been shown to play a variety of roles in cancer and in biological regulation - in resting T cells to "control the translation of viral RNA into protein." This is the last step in the creation of HIV antigens, which make the virus visible to the immune system. The team showed that a cluster of miRNAs bind to a certain location on the viral RNA, which in turn, blocks the creation of important proteins, and HIV replication. Resting CD4 T cells, they found, are "enriched" with more than the normal amount of these miRNAs compared to the activated T cells. When the researchers used antisense technology to block miRNA-caused viral inhibition, they found that the HIV again was active and able to replicate - proving miRNA's critical role in maintaining latency. While Dr. Zhang and his team continue to study how cellular miRNA contributes to latency, he notes that using miRNA inhibitors "might become a kind of therapeutic approach to get the virus out of hiding, making it visible and a target" for the immune system. "That's the next step," he says. Thomas Jefferson University | |||||||||||||||||||||
|
Related Immune System Current Events and Immune System News Articles Researcher tricks immune system in diabetic mice The body's immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it. New platinum-phosphate compounds kill ovarian cancer cells A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences. Landmark study defines benefits of early HIV testing and treatment for infected infants Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine. Stopping germs from ganging up on humans Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson. JDRF funded research shows promise for prevention, reversal of type 1 diabetes Researchers at the University of California, San Francisco have reported that two common cancer drugs have been used to block and reverse type 1 diabetes in mice. 2 new compounds show promise for eliminating breast cancer tumors Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors. Adalimumab may reduce health-care costs for Crohn's disease patients Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD). IBD occurs most frequently in people in their late teens and twenties. There have been cases in children as young as two years old and in older adults in their seventies and eighties; men and women have an equal chance of getting the disease. Purdue researcher invents molecule that stops SARS A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease. The miseries of allergies just may help prevent some cancers, study finds There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study. Researchers aim to over-stress already taxed mantle cell lymphoma cells Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them. More Immune System Current Events and Immune System News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||